Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 397 trials

Meningococcal Vaccine: Immune Response Study in Transgender and Cisgender Adults

We are investigating how healthy transgender and cisgender individuals aged 18 to 50 respond to the meningococcal serogroup B vaccine. This study aims to understand potential differences in immune responses between these groups.

Healthy Volunteers6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Chronic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with chronic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Chronic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology

Episodic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with episodic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Episodic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology

Triple-Negative Breast Cancer: Optimizing Pembrolizumab Use

We are studying whether observing patients after surgery is as effective as continuing pembrolizumab treatment for those who responded well to initial therapy. This trial also looks at safety, quality of life, and fertility impacts.

Early Triple-Negative Breast Cancer (TNBC)6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Heart Failure: CDR132L Treatment Study

We are comparing a new treatment, CDR132L, with a placebo for people with heart failure and left ventricular hypertrophy. The goal is to see if it improves heart function and structure better than standard care.

Heart Failure with Reduced Ejection Fraction6-12 monthsEfficacy phase (II)>20 visitsPartially RemoteCardiologyInternal Medicine

Chickenpox Vaccine Safety Study for Young Children

We are evaluating the safety of a new chickenpox vaccine for healthy children aged 12 to 15 months. This study compares it with an existing vaccine when given with other routine immunizations.

Chickenpox6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Chickenpox Vaccine Study for Children Aged 12 to 15 Months

We are evaluating a new chickenpox vaccine to see how well it works and its safety compared to the standard Varivax vaccine in healthy children. This study aims to ensure that the new vaccine provides a strong immune response.

Chickenpox6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Chronic Lung Disease in Premature Babies: OHB-607 Study

We are testing a new drug to see if it helps reduce lung disease in extremely premature infants compared to standard care. The study aims to improve their overall health and development.

Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Atrial Fibrillation After CABG: Anticoagulant Study

We are studying whether adding anticoagulant medications helps prevent blood clots in patients with new-onset atrial fibrillation after heart surgery. This trial aims to ensure safety and effectiveness in managing this condition.

Atrial FibrillationNew-Onset Post-Operative Atrial Fibrillation after CABG6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Immune Activation: FLAMOD Aerosol Treatment

We are testing a new aerosol treatment to see if it safely activates the immune system. This study aims to understand how well it works in stimulating local immune responses.

Pneumonia6-12 monthsSafety phase (I)Infectious DiseasesPulmonology

Dystonia: Botulinum Toxin for Arm Tremors

We are exploring how different tests and imaging techniques can help determine the effectiveness of botulinum toxin for treating arm tremors in people with dystonia. This study aims to improve treatment options for those affected.

Dystonic Tremor Syndrome6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Rheumatoid Arthritis: IMVT-1402 Treatment Study

We are evaluating a new treatment for adults with difficult-to-treat rheumatoid arthritis. The study aims to see if it helps improve symptoms compared to a placebo.

ACPA-Positive Rheumatoid Arthritis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Generalized Myasthenia Gravis: IMVT-1402 Study

We are testing a new treatment for people with mild to severe generalized myasthenia gravis. The study aims to see if it can improve muscle strength and reduce symptoms.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)Investigational MedicinesCost ReimbursementNeurology

Nevoid Basal Cell Carcinoma Syndrome: Sonidegib Treatment Study

We are studying the effects of Sonidegib on patients with Nevoid Basal Cell Carcinoma Syndrome and sporadic basal cell carcinoma. The trial will assess treatment effectiveness, safety, and quality of life improvements.

Nevoid Basal Cell Carcinoma Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Myelodysplastic Syndromes: Elritercept Treatment Study

We are testing elritercept to see if it can help reduce the need for blood transfusions in adults with certain types of myelodysplastic syndromes. The study will also look at how safe and tolerable the treatment is.

Myelodysplastic Syndrome (MDS)Anemia6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Efgartigimod for Early Treatment of Generalized Myasthenia Gravis

We are studying whether efgartigimod can improve daily activities and quality of life for patients with generalized myasthenia gravis and specific antibodies. This trial will help us understand its effectiveness and tolerability as an early treatment option.

Generalized Myasthenia Gravis6-12 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteNeurology

Migraine Aura: Amiloride Study

We are investigating whether amiloride can help prevent migraine aura and headaches in people who experience these symptoms. The study will also assess the safety of this medication.

Migraine Aura6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInternal MedicineNeurology

Cryoglobulinemia Vasculitis: Belimumab Study

We are studying whether belimumab can help people with non-infectious active cryoglobulinemia vasculitis compared to a placebo. The goal is to see if it improves symptoms and overall health.

Cryoglobulinemia Vasculitis6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInfectious DiseasesRheumatology

Bladder Cancer Treatment: BCG vs. BCG/EMDA-MMC

We are studying two treatment methods for high-risk non-muscle-invasive bladder cancer to see which is more effective and safer. This trial will help us understand the best approach to prevent disease progression.

Bladder Cancer6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsInternal MedicineUrology